Get started

Breakoutsignal

$BFRI entry PT 6 Target PT 11-20 and higherNote: ER 11/30 Tues Roth Capital analyst Jonathan Aschoff initiated coverage of BFRI stock with a buy rating and $20 price target. The analyst believes the stock is poised for growth thanks to its U.S. sales plans. Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
NASDAQ:BFRILong
by BADQOMOCAWGOWLD
American Express (AXP) bearish scenarioThe technical figure Channel Up can be found in the US company American Express (AXP) at daily chart. The American Express Company is a multinational corporation specialized in payment card services. The company was founded in 1850 and is one of the 30 components of the Dow Jones Industrial Average. The Channel Up has broken through the support line on 27/11/2021, if the price holds below this level you can have a possible bearish price movement with a forecast for the next 57 days towards 141.13 USD. Your stop loss order according to experts should be placed at 189.03 USD if you decide to enter this position. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NYSE:AXPShort
by legacyFXofficial
1
WTRH breakout from descending channel?I moronically sold some call options on this and missed out on the huge gains up towards $2.50. Am I seeing things hoping to make it back or is this another setup? Copying the gains from the last pump, another 200% gain would see WTRH back up towards $3. There is also a bullish divergence (red lines) that is also similar to the last dump and consolidation. This time it has happened over a much shorter time period, so it might be confirmation bias? Anyways, RSI bottoming out with a BuD, could be a juicy pump in the near future. NFA, aka Never Financially Adept, Naturally Fiscally Averse, NOT Free Avocados, and probably Not Financial Advice.
WLong
by EthIsTheFuture
$QLGNQualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.
NASDAQ:QLGNLong
by BADQOMOCAWGOWLD
4
$ISPCiSpecimen, Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables researchers to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
NASDAQ:ISPCLong
by BADQOMOCAWGOWLD
2
CHROMIA Breakout Done & Now Retesting. Ready To Go Higher!👉 CHRUSD Technical Indicators: ▫️ All EMA are placed below the price as supports. ▫️ Cup with Handle bullish pattern with breakout done. ▫️ Retest of the neckline in process. ▫️ Waiting now for a bounce strong enough, to take-off toward uptrend rally. 👉 CHRUSD Fundamental: ▫️ Chromia's Dev Team must also restore quickly confidence with its large community and investors who, following nearly 7 months of accumulation in a non-volatile range, are starting to seriously criticize the project and losing interest in it. This is the reason for this breakout, and the next few days, to be at a crucial time for #CHR short term future. Learn TA, Earn Money, and as usual Have Safe Trade. Enjoy this Sunday with family and loved ones.
BINANCE:CHRUSDLong
by alainbkk
$PROGProgenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
PLong
by BADQOMOCAWGOWLD
$LGVNLongeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
NASDAQ:LGVNLong
by BADQOMOCAWGOWLD
3
$RIVN entry PT 170-172 Target PT 198 and higherRivian Automotive, Inc. develops and manufactures electric adventure vehicles. It offers five-passenger pickup trucks and sports utility vehicles. The company provides electric SUVs and electric pickup vehicles. The company was founded in 2009 and is based in San Jose, California. It has additional facilities in Irvine, Carson, and Palo Alto, California; Normal, Illinois; Woking, United Kingdom; Plymouth, Michigan; Vancouver, Canada; and Wittman, Arizona.
NASDAQ:RIVNLong
by BADQOMOCAWGOWLD
Cardano Outlook (Nov/Dec)Cardano (ADA) is holding key support at the $2 level. If ADA can hold this level for the next few weeks, we could see an upward move and break-out from the symmetrical triangle showcased in the TA. The pink upward sloping line is strong long-term support and should provide a "lift-off" platform when we meet it in the early weeks of Dec (6th-9th). Should we have a dip before, it will provide support at the $1.75 level. *Note we could have a breakout before the first week of Dec. Traditionally these patterns breakout 70% of the way through the triangle. There are some resistance zones to break (green lines) as we make the move to the upside, with the final target for this break-out move set just below the $4 mark. This breakout move could play out over Jan/Feb. *Note this move will also depend on the movements of Bitcoin (BTC)
KRAKEN:ADAUSDLong
by DJCoope